The global Neurometabolic Disorders market size was valued at USD 1290.3 million in 2023 and is forecast to a readjusted size of USD 1733.3 million by 2030 with a CAGR of 4.3% during review period.
Neurometabolic disorders are genetic disorders that disrupt how the body uses or produces energy from food. When this happens, there may be too much of some chemicals (energy from food) or too little of others that are needed to stay healthy.
The Neurometabolic Disorders Market is driven by the increasing awareness and understanding of rare inherited metabolic disorders that affect the nervous system. These disorders, such as phenylketonuria and lysosomal storage diseases, require specialized treatments and therapies to manage symptoms and improve the quality of life for affected individuals. As advancements in genetics and diagnostics progress, the demand for research, development, and access to therapies and interventions for neurometabolic disorders continues to grow. These therapies often involve enzyme replacement therapy, gene therapy, or small molecule drugs, aiming to address the underlying metabolic abnormalities associated with these conditions. However, a key challenge for this market is the need to overcome the high cost of treatment and ensure that individuals with these rare disorders have equitable access to life-changing therapies. Regulatory approval, early diagnosis, and addressing potential side effects of treatments are ongoing challenges. Additionally, the market faces competition from other rare diseases, necessitating continuous research and efforts to mobilize resources and global commitment to improving the lives of those affected by neurometabolic disorders. Balancing innovation, affordability, and accessibility while addressing the unique challenges of these conditions is vital for the continued growth of the Neurometabolic Disorders Market.
This report includes an overview of the development of the Neurometabolic Disorders industry chain, the market status of Oral (Gaucher’s Disease, Fabry Disease), Parenteral (Gaucher’s Disease, Fabry Disease), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Neurometabolic Disorders.
Regionally, the report analyzes the Neurometabolic Disorders markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Neurometabolic Disorders market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Neurometabolic Disorders market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Neurometabolic Disorders industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., Gaucher’s Disease, Fabry Disease).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Neurometabolic Disorders market.
Regional Analysis: The report involves examining the Neurometabolic Disorders market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Neurometabolic Disorders market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Neurometabolic Disorders:
Company Analysis: Report covers individual Neurometabolic Disorders players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Neurometabolic Disorders This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Oral, Parenteral).
Technology Analysis: Report covers specific technologies relevant to Neurometabolic Disorders. It assesses the current state, advancements, and potential future developments in Neurometabolic Disorders areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Neurometabolic Disorders market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
Neurometabolic Disorders market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
Gaucher’s Disease
Fabry Disease
Pompe Disease
Mucopolysaccharidosis VI
Other
Market segment by Application
Oral
Parenteral
Market segment by players, this report covers
Amicus Therapeutics
ISU Abxis
JCR Pharmaceuticals
Biosidus
Greenovation Biotech
UAB Proforma
Dong-A Socio Group
ExSAR Corporation
Lixte Biotechnology
Neuraltus Pharmaceuticals
Protalix
Pharming Group
Protalix BioTherapeutics
Amicus
Biomarin
Genzyme
Shire
Greencross
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Argentina and Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Neurometabolic Disorders product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Neurometabolic Disorders, with revenue, gross margin and global market share of Neurometabolic Disorders from 2019 to 2024.
Chapter 3, the Neurometabolic Disorders competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2019 to 2030.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Neurometabolic Disorders market forecast, by regions, type and application, with consumption value, from 2025 to 2030.
Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Neurometabolic Disorders.
Chapter 13, to describe Neurometabolic Disorders research findings and conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.
1 Market Overview
1.1 Product Overview and Scope of Neurometabolic Disorders
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Neurometabolic Disorders by Type
1.3.1 Overview: Global Neurometabolic Disorders Market Size by Type: 2019 Versus 2023 Versus 2030
1.3.2 Global Neurometabolic Disorders Consumption Value Market Share by Type in 2023
1.3.3 Gaucher’s Disease
1.3.4 Fabry Disease
1.3.5 Pompe Disease
1.3.6 Mucopolysaccharidosis VI
1.3.7 Other
1.4 Global Neurometabolic Disorders Market by Application
1.4.1 Overview: Global Neurometabolic Disorders Market Size by Application: 2019 Versus 2023 Versus 2030
1.4.2 Oral
1.4.3 Parenteral
1.5 Global Neurometabolic Disorders Market Size & Forecast
1.6 Global Neurometabolic Disorders Market Size and Forecast by Region
1.6.1 Global Neurometabolic Disorders Market Size by Region: 2019 VS 2023 VS 2030
1.6.2 Global Neurometabolic Disorders Market Size by Region, (2019-2030)
1.6.3 North America Neurometabolic Disorders Market Size and Prospect (2019-2030)
1.6.4 Europe Neurometabolic Disorders Market Size and Prospect (2019-2030)
1.6.5 Asia-Pacific Neurometabolic Disorders Market Size and Prospect (2019-2030)
1.6.6 South America Neurometabolic Disorders Market Size and Prospect (2019-2030)
1.6.7 Middle East and Africa Neurometabolic Disorders Market Size and Prospect (2019-2030)
2 Company Profiles
2.1 Amicus Therapeutics
2.1.1 Amicus Therapeutics Details
2.1.2 Amicus Therapeutics Major Business
2.1.3 Amicus Therapeutics Neurometabolic Disorders Product and Solutions
2.1.4 Amicus Therapeutics Neurometabolic Disorders Revenue, Gross Margin and Market Share (2019-2024)
2.1.5 Amicus Therapeutics Recent Developments and Future Plans
2.2 ISU Abxis
2.2.1 ISU Abxis Details
2.2.2 ISU Abxis Major Business
2.2.3 ISU Abxis Neurometabolic Disorders Product and Solutions
2.2.4 ISU Abxis Neurometabolic Disorders Revenue, Gross Margin and Market Share (2019-2024)
2.2.5 ISU Abxis Recent Developments and Future Plans
2.3 JCR Pharmaceuticals
2.3.1 JCR Pharmaceuticals Details
2.3.2 JCR Pharmaceuticals Major Business
2.3.3 JCR Pharmaceuticals Neurometabolic Disorders Product and Solutions
2.3.4 JCR Pharmaceuticals Neurometabolic Disorders Revenue, Gross Margin and Market Share (2019-2024)
2.3.5 JCR Pharmaceuticals Recent Developments and Future Plans
2.4 Biosidus
2.4.1 Biosidus Details
2.4.2 Biosidus Major Business
2.4.3 Biosidus Neurometabolic Disorders Product and Solutions
2.4.4 Biosidus Neurometabolic Disorders Revenue, Gross Margin and Market Share (2019-2024)
2.4.5 Biosidus Recent Developments and Future Plans
2.5 Greenovation Biotech
2.5.1 Greenovation Biotech Details
2.5.2 Greenovation Biotech Major Business
2.5.3 Greenovation Biotech Neurometabolic Disorders Product and Solutions
2.5.4 Greenovation Biotech Neurometabolic Disorders Revenue, Gross Margin and Market Share (2019-2024)
2.5.5 Greenovation Biotech Recent Developments and Future Plans
2.6 UAB Proforma
2.6.1 UAB Proforma Details
2.6.2 UAB Proforma Major Business
2.6.3 UAB Proforma Neurometabolic Disorders Product and Solutions
2.6.4 UAB Proforma Neurometabolic Disorders Revenue, Gross Margin and Market Share (2019-2024)
2.6.5 UAB Proforma Recent Developments and Future Plans
2.7 Dong-A Socio Group
2.7.1 Dong-A Socio Group Details
2.7.2 Dong-A Socio Group Major Business
2.7.3 Dong-A Socio Group Neurometabolic Disorders Product and Solutions
2.7.4 Dong-A Socio Group Neurometabolic Disorders Revenue, Gross Margin and Market Share (2019-2024)
2.7.5 Dong-A Socio Group Recent Developments and Future Plans
2.8 ExSAR Corporation
2.8.1 ExSAR Corporation Details
2.8.2 ExSAR Corporation Major Business
2.8.3 ExSAR Corporation Neurometabolic Disorders Product and Solutions
2.8.4 ExSAR Corporation Neurometabolic Disorders Revenue, Gross Margin and Market Share (2019-2024)
2.8.5 ExSAR Corporation Recent Developments and Future Plans
2.9 Lixte Biotechnology
2.9.1 Lixte Biotechnology Details
2.9.2 Lixte Biotechnology Major Business
2.9.3 Lixte Biotechnology Neurometabolic Disorders Product and Solutions
2.9.4 Lixte Biotechnology Neurometabolic Disorders Revenue, Gross Margin and Market Share (2019-2024)
2.9.5 Lixte Biotechnology Recent Developments and Future Plans
2.10 Neuraltus Pharmaceuticals
2.10.1 Neuraltus Pharmaceuticals Details
2.10.2 Neuraltus Pharmaceuticals Major Business
2.10.3 Neuraltus Pharmaceuticals Neurometabolic Disorders Product and Solutions
2.10.4 Neuraltus Pharmaceuticals Neurometabolic Disorders Revenue, Gross Margin and Market Share (2019-2024)
2.10.5 Neuraltus Pharmaceuticals Recent Developments and Future Plans
2.11 Protalix
2.11.1 Protalix Details
2.11.2 Protalix Major Business
2.11.3 Protalix Neurometabolic Disorders Product and Solutions
2.11.4 Protalix Neurometabolic Disorders Revenue, Gross Margin and Market Share (2019-2024)
2.11.5 Protalix Recent Developments and Future Plans
2.12 Pharming Group
2.12.1 Pharming Group Details
2.12.2 Pharming Group Major Business
2.12.3 Pharming Group Neurometabolic Disorders Product and Solutions
2.12.4 Pharming Group Neurometabolic Disorders Revenue, Gross Margin and Market Share (2019-2024)
2.12.5 Pharming Group Recent Developments and Future Plans
2.13 Protalix BioTherapeutics
2.13.1 Protalix BioTherapeutics Details
2.13.2 Protalix BioTherapeutics Major Business
2.13.3 Protalix BioTherapeutics Neurometabolic Disorders Product and Solutions
2.13.4 Protalix BioTherapeutics Neurometabolic Disorders Revenue, Gross Margin and Market Share (2019-2024)
2.13.5 Protalix BioTherapeutics Recent Developments and Future Plans
2.14 Amicus
2.14.1 Amicus Details
2.14.2 Amicus Major Business
2.14.3 Amicus Neurometabolic Disorders Product and Solutions
2.14.4 Amicus Neurometabolic Disorders Revenue, Gross Margin and Market Share (2019-2024)
2.14.5 Amicus Recent Developments and Future Plans
2.15 Biomarin
2.15.1 Biomarin Details
2.15.2 Biomarin Major Business
2.15.3 Biomarin Neurometabolic Disorders Product and Solutions
2.15.4 Biomarin Neurometabolic Disorders Revenue, Gross Margin and Market Share (2019-2024)
2.15.5 Biomarin Recent Developments and Future Plans
2.16 Genzyme
2.16.1 Genzyme Details
2.16.2 Genzyme Major Business
2.16.3 Genzyme Neurometabolic Disorders Product and Solutions
2.16.4 Genzyme Neurometabolic Disorders Revenue, Gross Margin and Market Share (2019-2024)
2.16.5 Genzyme Recent Developments and Future Plans
2.17 Shire
2.17.1 Shire Details
2.17.2 Shire Major Business
2.17.3 Shire Neurometabolic Disorders Product and Solutions
2.17.4 Shire Neurometabolic Disorders Revenue, Gross Margin and Market Share (2019-2024)
2.17.5 Shire Recent Developments and Future Plans
2.18 Greencross
2.18.1 Greencross Details
2.18.2 Greencross Major Business
2.18.3 Greencross Neurometabolic Disorders Product and Solutions
2.18.4 Greencross Neurometabolic Disorders Revenue, Gross Margin and Market Share (2019-2024)
2.18.5 Greencross Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Neurometabolic Disorders Revenue and Share by Players (2019-2024)
3.2 Market Share Analysis (2023)
3.2.1 Market Share of Neurometabolic Disorders by Company Revenue
3.2.2 Top 3 Neurometabolic Disorders Players Market Share in 2023
3.2.3 Top 6 Neurometabolic Disorders Players Market Share in 2023
3.3 Neurometabolic Disorders Market: Overall Company Footprint Analysis
3.3.1 Neurometabolic Disorders Market: Region Footprint
3.3.2 Neurometabolic Disorders Market: Company Product Type Footprint
3.3.3 Neurometabolic Disorders Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 Market Size Segment by Type
4.1 Global Neurometabolic Disorders Consumption Value and Market Share by Type (2019-2024)
4.2 Global Neurometabolic Disorders Market Forecast by Type (2025-2030)
5 Market Size Segment by Application
5.1 Global Neurometabolic Disorders Consumption Value Market Share by Application (2019-2024)
5.2 Global Neurometabolic Disorders Market Forecast by Application (2025-2030)
6 North America
6.1 North America Neurometabolic Disorders Consumption Value by Type (2019-2030)
6.2 North America Neurometabolic Disorders Consumption Value by Application (2019-2030)
6.3 North America Neurometabolic Disorders Market Size by Country
6.3.1 North America Neurometabolic Disorders Consumption Value by Country (2019-2030)
6.3.2 United States Neurometabolic Disorders Market Size and Forecast (2019-2030)
6.3.3 Canada Neurometabolic Disorders Market Size and Forecast (2019-2030)
6.3.4 Mexico Neurometabolic Disorders Market Size and Forecast (2019-2030)
7 Europe
7.1 Europe Neurometabolic Disorders Consumption Value by Type (2019-2030)
7.2 Europe Neurometabolic Disorders Consumption Value by Application (2019-2030)
7.3 Europe Neurometabolic Disorders Market Size by Country
7.3.1 Europe Neurometabolic Disorders Consumption Value by Country (2019-2030)
7.3.2 Germany Neurometabolic Disorders Market Size and Forecast (2019-2030)
7.3.3 France Neurometabolic Disorders Market Size and Forecast (2019-2030)
7.3.4 United Kingdom Neurometabolic Disorders Market Size and Forecast (2019-2030)
7.3.5 Russia Neurometabolic Disorders Market Size and Forecast (2019-2030)
7.3.6 Italy Neurometabolic Disorders Market Size and Forecast (2019-2030)
8 Asia-Pacific
8.1 Asia-Pacific Neurometabolic Disorders Consumption Value by Type (2019-2030)
8.2 Asia-Pacific Neurometabolic Disorders Consumption Value by Application (2019-2030)
8.3 Asia-Pacific Neurometabolic Disorders Market Size by Region
8.3.1 Asia-Pacific Neurometabolic Disorders Consumption Value by Region (2019-2030)
8.3.2 China Neurometabolic Disorders Market Size and Forecast (2019-2030)
8.3.3 Japan Neurometabolic Disorders Market Size and Forecast (2019-2030)
8.3.4 South Korea Neurometabolic Disorders Market Size and Forecast (2019-2030)
8.3.5 India Neurometabolic Disorders Market Size and Forecast (2019-2030)
8.3.6 Southeast Asia Neurometabolic Disorders Market Size and Forecast (2019-2030)
8.3.7 Australia Neurometabolic Disorders Market Size and Forecast (2019-2030)
9 South America
9.1 South America Neurometabolic Disorders Consumption Value by Type (2019-2030)
9.2 South America Neurometabolic Disorders Consumption Value by Application (2019-2030)
9.3 South America Neurometabolic Disorders Market Size by Country
9.3.1 South America Neurometabolic Disorders Consumption Value by Country (2019-2030)
9.3.2 Brazil Neurometabolic Disorders Market Size and Forecast (2019-2030)
9.3.3 Argentina Neurometabolic Disorders Market Size and Forecast (2019-2030)
10 Middle East & Africa
10.1 Middle East & Africa Neurometabolic Disorders Consumption Value by Type (2019-2030)
10.2 Middle East & Africa Neurometabolic Disorders Consumption Value by Application (2019-2030)
10.3 Middle East & Africa Neurometabolic Disorders Market Size by Country
10.3.1 Middle East & Africa Neurometabolic Disorders Consumption Value by Country (2019-2030)
10.3.2 Turkey Neurometabolic Disorders Market Size and Forecast (2019-2030)
10.3.3 Saudi Arabia Neurometabolic Disorders Market Size and Forecast (2019-2030)
10.3.4 UAE Neurometabolic Disorders Market Size and Forecast (2019-2030)
11 Market Dynamics
11.1 Neurometabolic Disorders Market Drivers
11.2 Neurometabolic Disorders Market Restraints
11.3 Neurometabolic Disorders Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 Industry Chain Analysis
12.1 Neurometabolic Disorders Industry Chain
12.2 Neurometabolic Disorders Upstream Analysis
12.3 Neurometabolic Disorders Midstream Analysis
12.4 Neurometabolic Disorders Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
Amicus Therapeutics
ISU Abxis
JCR Pharmaceuticals
Biosidus
Greenovation Biotech
UAB Proforma
Dong-A Socio Group
ExSAR Corporation
Lixte Biotechnology
Neuraltus Pharmaceuticals
Protalix
Pharming Group
Protalix BioTherapeutics
Amicus
Biomarin
Genzyme
Shire
Greencross
Ěý
Ěý
*If Applicable.
